Akshit Chitkara, MD

Hematolgy-Oncology🦀Fellow at @KimmelCancerCtr TJU 2024-27
Former IM Chief Resident @UCRiverside
Former California Med. Asso., Resident & Fellow Delegate

[OncLive.com @OncLive]

📚🤝 #FellowsForum is not just about education. It’s also about networking, collaboration, team-building, and learning how to become future panelists, discussants, and leaders in oncology.

🦈 A highlight was the innovative #TKITank team led by @benlevylungdoc , where team pitched ideas in a Shark Tank-style format showcasing the project of @Jani_Chinmay and @GlopesMd in collaboration with @Larvol , exploring how AI can be leveraged to support clinical decision-making in oncology. 🤖🎯

💡 These interactive experiences spark creativity, strengthen collaborations, and build relationships that extend far beyond the conference itself.
#ASCO26 #Oncology #AIinOncology #MedEd #FutureLeaders 🚀
@JamesFanWu @chitkaramd @nehemias

[Akshit Chitkara, MD @chitkaramd]

Kickstarting ASCO2026 by presenting findings from our study evaluating role of AI decision support in rapidly evolving therapeutic landscape! #OncLive #ASCO2026 #AI

[Akshit Chitkara, MD @chitkaramd]

Honored to present our latest research findings at the OncLive National Fellows Forum in San Francisco! 🌉 Grateful for the opportunity to share this work and engage with such a brilliant group of peers and mentors.
#OncLive #Oncology #GUoncology

[Akshit Chitkara, MD @chitkaramd]

Presenting our findings on sequential ARPI therapy in mCRPC! 🧬
So grateful to be backed by the best mentors, Dr. Zarrabi and Dr. Tester. 🙌
@ASCO

[Akshit Chitkara, MD @chitkaramd]

Excellent keynote presentation on AI in cancer care at PSOH annual meeting 2025 by @DrArturoAI

[Akshit Chitkara, MD @chitkaramd]

Day 2 ASCO Philly starts strong with @PBarataMD spotlighting prostate cancer highlights from ASCO 2025! MMAI-driven risk stratification is making waves in prostate cancer space, promising times ahead!

[Akshit Chitkara, MD @chitkaramd]

Kicking off ASCO Direct Philly 2025 with an excellent overview by @DrBonillaOnc, highlighting key clinical trials in the non-CRC space!

Thank you @ASCO for bringing these important updates to the forefront.

[Vincent Rajkumar @VincentRK]

Key Myeloma therapy update for 2025

1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd).

2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use.

3) Maintenance: Doublet maintenance with Dara/ Len or bortezomib/ Len for high risk myeloma. Either Single or Doublet maintenance for standard risk.

4) Use new IMWG IMS risk stratification

5) First relapse: standard triplet therapy is fine for most. CART in first relapse mainly for functional high risk (progression or early relapse with induction).

6) When using CART, disease burden should be controlled and minimal to reduce risk of serious toxicity.

[Rohit Singh, MD @RohitBanwar]

📚 Join us at #ASCO25 for Publication 101: Peer Review & Becoming a Successful Author
🗓️ June 2 | ⏰ 10:15–11:15 AM
📍Trainee & Early Career Lounge

Get practical tips to boost your academic writing, peer-review & publishing success!
#OncTwitter #ASCO #ASCOTECAG #UVM

[Udhayvir Grewal @UGrewalMD]

Breaking News! (Quite literally 😍) #ASCO25

🚨 BREAKWATER trial (NEJM): EC + mFOLFOX6 sets new 1L standard in BRAF V600E-mutant mCRC

➡️OS: 30.3 vs 15.1 mo (HR 0.49, P<0.001)
➡️PFS: 12.8 vs 7.1 mo (HR 0.53, P<0.001)
⚠️ Grade ≥3 AEs: 46.1% vs 38.9% — manageable, consistent with known profiles

📄 https://t.co/qjMbPfONph
#GIonc #mCRC #OncoTwitter #BRAF

[Oncology Brothers @OncBrothers]

#ToxCheck: AntiVEGF &amp; AntiEGFR have been approved for years. Just before #GI25, w/ @pashtoonkasi we 🗣️ key AEs &amp; management strategies for these drugs!

Full 📢
⭐️ https://t.co/3f0DSs2MsY
⭐️ “Oncology Brothers” podcast

#OncTwitter #bevacizumab #panitumumab #cetuximab #crcsm

[Akshit Chitkara, MD @chitkaramd]

🩸Excited to share our work on catheter-related thrombosis! We tackle the big ques: How do we best prevent &amp; manage CRDVT?

Grateful to @Clotmaster for the opportunity!

🔗Read here https://t.co/WoMuvjeFxg

@TJUHospital @JeffersonUniv @ASH_hematology @EHA_Hematology #Thrombosis

[Akshit Chitkara, MD @chitkaramd]

@nikhil_vojjala @ASCO @vijsinghmd @ibrahimazaronc @KarmanosHemeOnc @THO_WSU_IM Congratulations 🎉

[Akshit Chitkara, MD @chitkaramd]

Still getting asked about this key meta-analysis! 📢 In the evolving landscape of HER2-low tumors, we explored HER2-targeted treatments in HER2+ mCRC. Check it out! #GIOnc #HER2 #CRC #OncologyResearch

[Akshit Chitkara, MD @chitkaramd]

📢Publication alert 🚨
Excited to share our research that has been published in Current Oncology studying the efficacy of HER2-Targeted treatment regimens in HER2-Positive mCRC.

https://t.co/ODQvGpYMAh

Special thanks to my mentor and guide Dr. @AnwaarSaeed3 for believing in me.

Sincere gratitude to @IbrahimSahinMD1 @DennisJHsu @JanieYZhang @AnamikaAdib @sepideh_gholami for all the guidance and support!

@UPMCHillmanCC @pitthem @UCRiverside @HemOncFellows @mdpiopenaccess @img_oncologists

#GIOncology #HematologyOncology #Match2024 #Onctwitter #Medtwitter #HOfellows

[Udhayvir Grewal @UGrewalMD]

Great discussion on updates in anal cancer by @CathyEngMD #GI25

Anal cancer incidence rising, early stage most common. 5-year OS 36%

📌 Locally advanced anal cancer:
-No role for radiosensitizing chemo- RTOG98-11, ACTII
-5-FU-MMC remains SOC (cisplatin may be more appropriate in immunosupp pts, 5-FU in frail pts)
-no randomized data, but cape can be considered as an alternative to 5-FU, myelosupp may be an issue.
-IO in this setting-no role, ongoing studies.
-no role for adjuvant or maintenance therapy.

📌Advanced anal cancer:
-InterAACT: carbo-taxol became SOC due to similar ORR and better safety profile.
-POD1UM-303: Retifanlimab+carbo+taxol (compared to carbo+taxol) in metastatic treatment naive metastatic anal SCC: PFS improvement, ORR 56% trend for OS improvement. HIV + pts included. Now an NCCN 2B recommendation.
-EA2176: Carbo/taxol with or without Nivo- PFS primary endpoint, ctDNA incorporated. Finished enrolment. HIV+ pts included.

[Akshit Chitkara, MD @chitkaramd]

Thank you 🙏🏻
Day 3 ASCO GI 2025!

[Udhayvir Grewal @UGrewalMD]

Congratulations @atulya_khosla and @chitkaramd on all the amazing work at #GI25 👏🏻 ⭐️

[Akshit Chitkara, MD @chitkaramd]

Excellent CRC review by @OncBrothers and @CathyEngMD #ASCOGI2025

[Akshit Chitkara, MD @chitkaramd]

Excellent work on NETs @UGrewalMD 👏🏻👏🏻

[Udhayvir Grewal @UGrewalMD]

Im bummed that my mentor @ChandrikhaC is not at #GI25 to cheer me on, but excited to present our analysis on (well-differentiated) early-onset small bowel NETs. #NETsatGI25
Poster board F13

Excited to build upon the evolving understanding of early-onset NENs. There’s a lot of work that needs to be done. More to come from @UIowaCancer

Cc: @SempriniJason

[Rajat Thawani @rajatthawani]

Lung cancer leading the pack with new FDA approvals in 2024!
#lcsm

[Akshit Chitkara, MD @chitkaramd]

Presented our research at San Antonio Breast Cancer Symposium 2024, studying breast cancer disparities in males. 🔥🔥
This project wouldn’t have been possible without the mentorship of my mentor @anamarialopezmd 🙌🏻

https://t.co/E0Ioz2IwIb